keyword
MENU ▼
Read by QxMD icon Read
search

metformin users

keyword
https://www.readbyqxmd.com/read/29168915/a-novel-microdevice-for-rapid-neutrophil-purification-and-phenotyping-in-type-2-diabetes-mellitus
#1
Hui Min Tay, Rinkoo Dalan, King Ho Holden Li, Bernhard O Boehm, Han Wei Hou
Neutrophil dysfunction is strongly linked to type 2 diabetes mellitus (T2DM) pathophysiology, but the prognostic potential of neutrophil biomarkers remains largely unexplored due to arduous leukocyte isolation methods. Herein, a novel integrated microdevice is reported for single-step neutrophil sorting and phenotyping (chemotaxis and formation of neutrophil extracellular traps (NETosis)) using small blood volumes (fingerprick). Untouched neutrophils are purified on-chip from whole blood directly using biomimetic cell margination and affinity-based capture, and are exposed to preloaded chemoattractant or NETosis stimulant to initiate chemotaxis or NETosis, respectively...
November 23, 2017: Small
https://www.readbyqxmd.com/read/29144162/association-between-metformin-adherence-and-all-cause-mortality-among-new-users-of-metformin-a-nested-case-control-study
#2
Patrice Simard, Nancy Presse, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel, Sylvie Perreault
BACKGROUND: Metformin presents better survival rates than other oral antidiabetics in the treatment of type 2 diabetes. However, these benefits may be dampened by inadequate treatment adherence. OBJECTIVE: We aimed to investigate the relationship between adherence level to metformin therapy and all-cause mortality over 10 years in incident metformin users. METHODS: A nested case-control study was conducted using a large cohort of beneficiaries of the Quebec public drug insurance plan, aged 45 to 85 years, who initiated metformin between 2000 and 2009...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29138876/lower-risk-of-dementia-with-pioglitazone-compared-with-other-second-line-treatments-in-metformin-based-dual-therapy-a-population-based-longitudinal-study
#3
Chieh-Hsiang Lu, Chen-Yi Yang, Chung-Yi Li, Cheng-Yang Hsieh, Huang-Tz Ou
AIMS/HYPOTHESIS: The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy. METHODS: A total of 204,323 individuals with type 2 diabetes aged ≥18 years who were stable metformin users and dementia-free before the initiation of second-line glucose-lowering medication were identified in the period 2000-2011 from Taiwan's National Health Insurance Research Database and followed to the end of 2013...
November 14, 2017: Diabetologia
https://www.readbyqxmd.com/read/29108130/comparative-risk-of-serious-hypoglycemia-with-oral-antidiabetic-monotherapy-a-retrospective-cohort-study
#4
Charles E Leonard, Xu Han, Colleen M Brensinger, Warren B Bilker, Serena Cardillo, James H Flory, Sean Hennessy
PURPOSE: To examine and compare risks of serious hypoglycemia among antidiabetic monotherapy-treated adults receiving metformin, a sulfonylurea, a meglitinide, or a thiazolidinedione. METHODS: We performed a retrospective cohort study of apparently new users of monotherapy with metformin, glimepiride, glipizide, glyburide, pioglitazone, rosiglitazone, nateglinide, or repaglinide within a dataset of Medicaid beneficiaries from California, Florida, New York, Ohio, and Pennsylvania...
November 6, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29075499/metformin-therapy-and-postoperative-atrial-fibrillation-in-diabetic-patients-after-cardiac-surgery
#5
Suresh Basnet, Andrzej Kozikowski, Haiyan Sun, Melissa Troup, Luis E Urrutia, Renee Pekmezaris
BACKGROUND: Postoperative atrial fibrillation (AF) commonly occurs in cardiac surgery patients. Studies suggest inflammation and oxidative stress contribute to postoperative AF development in this patient population. Metformin exerts an anti-inflammatory effect that reduces oxidative stress and thus may play a role in preventing postoperative AF. METHODS: We conducted a matched, retrospective cohort study of diabetic patients' age ≥18 undergoing a coronary artery bypass graft (CABG) and/or cardiac valve surgery from January 1, 2009, to November 30, 2014...
2017: Journal of Intensive Care
https://www.readbyqxmd.com/read/29069850/metformin-use-and-survival-outcomes-in-endometrial-cancer-a-systematic-review-and-meta-analysis
#6
Weimin Xie, Tianjia Li, Jing Yang, Mengmeng Shang, Ying Xiao, Qian Li, Jiaxin Yang
Previous studies have evaluated the effects of metformin use on survival outcomes in endometrial cancer, but their results are inconsistent. We conducted a systematic review and meta-analysis to provide a quantitative assessment of the drug's effects based on available evidence. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify relevant studies that evaluated the association between metformin use on survival outcomes in endometrial cancer. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association of metformin use with overall survival and with progression-free survival using a fixed-effects model...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29063073/the-association-between-metformin-use-and-colorectal-cancer-survival-among-patients-with-diabetes-mellitus-an-updated-meta-analysis
#7
Shan Tian, Hong-Bo Lei, Yu-Lan Liu, Yan Chen, Wei-Guo Dong
OBJECTIVE: Recent studies have reported conflicting results on the correlation between metformin use and outcomes in patients with colorectal cancer (CRC). A meta-analysis was performed to evaluate the efficacy of metformin therapy on the prognosis of CRC patients with type 2 diabetes mellitus (T2DM). METHODS: We conducted a systematic search of PubMed, EMBASE, the Cochrane Library, and the Web of Science for related articles up to August 2016. Two investigators independently identified and extracted information...
September 2017: Chronic Dis Transl Med
https://www.readbyqxmd.com/read/29054569/cause-specific-mortality-in-endometrioid-endometrial-cancer-patients-with-type-2-diabetes-using-metformin-or-other-types-of-antidiabetic-medication
#8
R Arima, A Hautakoski, M Marttila, M Arffman, R Sund, P Ilanne-Parikka, J Kangaskokko, M Hinkula, U Puistola, E Läärä
AIM: To obtain further evidence of the association between metformin or other types of antidiabetic medication (ADM) and mortality from endometrial cancer (EC) and other causes of death in patients with endometrioid EC and type 2 diabetes (T2D). MATERIALS AND METHODS: A retrospective cohort of women with existing T2D and diagnosed with endometrioid EC from 1998 to 2011, obtained from a nationwide diabetes database (FinDM), were included in the study. Cumulative mortality from EC and that from other causes was described by using the Aalen-Johansen estimator...
October 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29051159/metformin-use-may-moderate-the-effect-of-dpp-4-inhibitors-on-cardiovascular-outcomes
#9
Matthew J Crowley, John W Williams, Andrzej S Kosinski, David A D'Alessio, John B Buse
OBJECTIVE: To explore prevalent metformin use as a potential moderator of the cardiovascular effects of dipeptidyl peptidase 4 inhibitors (DPP-4i). RESEARCH DESIGN AND METHODS: We performed a meta-analysis of the three major cardiovascular outcomes trials examining DPP-4i. We used meta-regression to examine how the cardiovascular effects of DPP-4i differ between prevalent metformin users and baseline nonusers. RESULTS: While prevalent metformin users experienced a trend toward improved cardiovascular outcomes with DPP-4i (summary hazard ratio [HR] 0...
October 19, 2017: Diabetes Care
https://www.readbyqxmd.com/read/29049093/association-of-metformin-use-and-survival-outcome-in-women-with-cervical-cancer
#10
Tsuyoshi Takiuchi, Hiroko Machida, Marianne S Hom, Sayedamin Mostofizadeh, Marina Frimer, Laurie L Brunette, Koji Matsuo
OBJECTIVE: Although preclinical studies suggest possible antitumor effects of metformin against cervical cancer, there is currently a lack of clinical data examining the association of metformin use and survival in women with cervical cancer. The aim of this study was to examine survival of women with cervical cancer who were receiving metformin. METHODS: This is a retrospective study examining consecutive cases of stages I to IV cervical cancer between 2000 and 2014...
September 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29032229/sulfonylureas-as-initial-treatment-for-type-2-diabetes-and-the-risk-of-severe-hypoglycemia
#11
Oriana Yu, Laurent Azoulay, Hui Yin, Kristian B Filion, Samy Suissa
PURPOSE: The magnitude of the risk of severe hypoglycemia associated with sulfonylureas as the initial treatment for type 2 diabetes in the real-world setting is unknown. We assessed the risk of severe hypoglycemia associated with initiating monotherapy with sulfonylurea compared to metformin for the treatment of type 2 diabetes. METHODS: Using the UK Clinical Practice Research Datalink and Hospital Episode Statistics linked to the Office for National Statistics, we identified a cohort of patients with type 2 diabetes who initiated sulfonylureas or metformin monotherapy between April 1, 1998 and December 31, 2012, with follow-up until December 31, 2013...
October 12, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/29029501/metformin-and-endometrial-cancer-survival-a-quantitative-synthesis-of-observational-studies
#12
Jianfeng Guo, Kai Xu, Min An, Yingchao Zhao
Metformin has been reported to have anticancer effect and can affect patient survival in several malignancies. However, the results are inconclusive for endometrial cancer. Hence, we conducted a systematic review and meta-analysis to investigate the prognostic role of metformin in patients with endometrial cancer. Studies were identified from Pubmed and Embase database through March 2017. Observational studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were selected...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29026839/missing-the-benefit-of-metformin-in-acute-myeloid-leukemia-a-problem-of-contrast
#13
Alice C Ceacareanu, George K Nimako, Zachary A P Wintrob
OBJECTIVE: To evaluate whether metformin's cancer-related benefits reported in patients with solid tumors (ST) are also present in acute myeloid leukemia (AML) patients. METHODS: Baseline demographic and clinical history for all diabetes mellitus patients newly diagnosed with AML or cancer of the breast, ovary, prostate, gastrointestinal tract, lung, or kidney at Roswell Park Cancer Institute in Buffalo, NY (January 2003-December 2010, n = 924) was collected. Overall survival (OS) and disease-free survival (DFS) were assessed by Kaplan-Meier (KM) analysis and Cox proportional hazards regression (hazard ratio [HR])...
July 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29016549/depressive-symptoms-antidepressant-medication-use-and-inflammatory-markers-in-the-diabetes-prevention-program
#14
Mary de Groot, David Marrero, Lisa Mele, Todd Doyle, Frank Schwartz, Kieren J Mather, Ronald Goldberg, David W Price, Yong Ma, William C Knowler
OBJECTIVE: Antidepressant medication use (ADM) has been shown to predict diabetes. This paper assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). METHODS: DPP participants randomized to Metformin (MET), Lifestyle Intervention (ILS) or placebo (PLB) were assessed for depression (BDI; Beck Depression Inventory) annually; ADM use semi-annually; serum inflammatory markers (CRP, IL-6) at baseline and Year 1; and diagnosis of T2DM semi-annually (over 3...
October 10, 2017: Psychosomatic Medicine
https://www.readbyqxmd.com/read/28954880/metformin-vs-sulfonylurea-use-and-risk-of-dementia-in-us-veterans-aged-%C3%A2-65-years-with-diabetes
#15
Ariela R Orkaby, Kelly Cho, Jean Cormack, David R Gagnon, Jane A Driver
OBJECTIVE: To determine whether metformin is associated with a lower incidence of dementia than sulfonylureas. METHODS: This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia. Follow-up began after 2 years of therapy. To account for confounding by indication, we developed a propensity score (PS) and used inverse probability of treatment weighting (IPTW) methods...
October 31, 2017: Neurology
https://www.readbyqxmd.com/read/28927103/lack-of-chemopreventive-efficacy-of-metformin-in-rodent-models-of-urinary-bladder-head-and-neck-and-colon-intestine-cancer
#16
Matthew D Thompson, Ronald A Lubet, David L Mccormick, Margie L Clapper, Ann M Bode, M Margaret Juliana, Fariba Moeinpour, Clinton J Grubbs
Metformin is a biguanide employed in treating type II diabetes. Its potential efficacy for treating cancer has been demonstrated epidemiologically (lower cancer incidence in metformin users compared with users of sulfonylureas or insulin) and mechanistically, primarily in cell culture. Metformin decreases the levels of insulin-like growth factor 1 and secondarily inhibits the mammalian target of rapamycin pathway to exhibit anticancer effects. The current study examined its cancer preventive efficacy in multiple standard in situ arising cancer models...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28915960/pleiotropic-effects-of-metformin-to-rescue-statin-induced-muscle-injury-and-insulin-resistance-a-proposed-mechanism-and-potential-clinical-implications
#17
Nicholas W Carris, Srinivas M Tipparaju, David J Magness, Kalyan C Chapalamadugu, Ronald R Magness
The 2013 American Heart Association Blood Cholesterol Guidelines increased the number of patients recommended for statin therapy in the United States to 56million. Two common statin side effects are muscle pain, referred to as "statin-associated muscle symptoms", and increased risk for new onset type-2-diabetes mellitus. Up to 25% of statin users report muscle symptoms resulting in many patients being switched to lower dose or lower potency statins, or refusing statins altogether. The most likely signaling mechanisms for statin-associated muscle symptoms overlaps with the proposed mechanism of statin-induced insulin resistance...
September 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28866826/impact-of-pioglitazone-regulatory-withdrawal-on-antidiabetic-drug-use-and-health-in-diabetic-patients
#18
Antoine Pariente, Yohann Mansiaux, Ana Jarné, Francesco Salvo, Cécile Pageot, Julien Bezin, Andy Smith, Bernard Bégaud
PURPOSE: In 2011, pioglitazone was withdrawn from the French market owing to a potential risk of bladder cancer. This study aimed at assessing the impact of this pioglitazone withdrawal (PW) considering (i) trends in antidiabetic uses and (ii) changes in hospitalization/death rates in diabetic patients following PW. METHODS: We first considered the general population of the Echantillon Généraliste des Bénéficiaires (EGB), a 1/97th representative sample of the French healthcare insurance system beneficiaries, for the 2010-2014 period...
December 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28861893/glitazone-use-associated-with-reduced-risk-of-parkinson-s-disease
#19
Brage Brakedal, Irene Flønes, Simone F Reiter, Øivind Torkildsen, Christian Dölle, Jörg Assmus, Kristoffer Haugarvoll, Charalampos Tzoulis
BACKGROUND: Whether antidiabetic glitazone drugs protect against Parkinson's disease remains controversial. Although a single clinical trial showed no evidence of disease modulation, retrospective studies suggest that a disease-preventing effect may be plausible. The objective of this study was to examine if the use of glitazone drugs is associated with a lower incidence of PD among diabetic patients. METHODS: We compared the incidence of PD between individuals with diabetes who used glitazones, with or without metformin, and individuals using only metformin in the Norwegian Prescription Database...
September 1, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28840596/risk-of-cause-specific-death-in-individuals-with-cancer-modifying-role-diabetes-statins-and-metformin
#20
Jari Haukka, Leo Niskanen, Anssi Auvinen
Both diabetes mellitus (DM) and cancer are common diseases and they frequently occur in the same patients. We investigated the all-cause and cause-specific mortality dynamics in relation to baseline DM, statin use and metformin use. The study population consisted of 39,900 incident cancer cases from Finland, 19,822 patients were free of DM at the start of follow-up and 20,078 had DM. Mortality from all causes, and cancer, cardiovascular (CVD) and other causes was analysed using Poisson regression model with the following variables: sex, age, DM, statin and metformin usage in baseline, cancer type and stage and calendar period...
December 15, 2017: International Journal of Cancer. Journal International du Cancer
keyword
keyword
90703
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"